One of Merck’s pivotal stomach cancer trials for Keytruda flops, just months after an FDA OK

Less than three months after Merck $MRK won an accelerated OK to market Keytruda as a third-line drug for stomach cancer, the pharma giant says their checkpoint failed to produce either positive overall survival data or progression-free survival results for the same indication in a second-line setting.

The pivotal Phase III flop for advanced gastric or gastroesophageal junction adenocarcinoma marks the latest in a long string of often surprising hits and misses in the checkpoint field.

Roy Baynes

For Merck, which has hundreds of trials running around Keytruda, the focus now shifts to KEYNOTE-062, a Phase III clinical trial studying Keytruda as a monotherapy or in combination with chemotherapy as first-line treatment for patients with PD-L1 positive advanced gastric or gastroesophageal junction cancer. There is also KEYNOTE-585, a Phase III trial studying Keytruda (pembrolizumab) in combination with chemotherapy in a neoadjuvant/adjuvant setting.

Merck has been steadily gaining market ground on Bristol-Myers Squibb $BMY, the leader in checkpoints, after a string of successful trials for lung cancer. Bristol-Myers Squibb also has third-line approval for Opdivo in gastric cancer, in indication which just days ago defeated a Phase III mounted by Bavencio from Pfizer and Merck KGaA. Bavencio was tested against chemo rather than a placebo.

“We remain committed to the continued study of Keytruda for gastric cancers and finding new options for patients facing this difficult-to-treat cancer type across various treatment settings,” said Roy Baynes, chief medical officer at Merck Research Laboratories, in a statement.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Research Scientist - Disease Biology
Recursion Pharmaceuticals Salt Lake City, UT
Senior Scientist - Predictive Pharmacology
Recursion Pharmaceuticals Salt Lake City, UT
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA
Director of Marketing
twoXAR Mountain View, CA

Visit Endpoints Careers ->